Reata Pharma
(RETA)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 22,746 | 195 | 0 | 540 | 762 |
| Cost of Goods | 846 | N/A | N/A | N/A | N/A |
| Gross Profit | 21,900 | 195 | 0 | 540 | 762 |
| Operating Expenses | 114,949 | 110,650 | 79,523 | 71,027 | 64,747 |
| Operating Income | -92,203 | -110,455 | -79,523 | -70,487 | -63,985 |
| Other Income | 285,201 | -5,662 | -6,034 | -8,515 | -9,571 |
| Pre-tax Income | 192,998 | -116,117 | -85,557 | -79,002 | -73,556 |
| Income Tax | 0 | N/A | -55 | N/A | -1 |
| Net Income Continuous | 192,998 | -116,117 | -85,502 | -79,002 | -73,555 |
| Net Income | $192,998 | $-116,117 | $-85,502 | $-79,002 | $-73,555 |
| EPS Basic Total Ops | 5.12 | -3.14 | -2.33 | -2.16 | -2.02 |
| EPS Basic Continuous Ops | 5.12 | -3.14 | -2.33 | -2.16 | -2.02 |
| EPS Diluted Total Ops | 4.65 | -3.14 | -2.33 | -2.16 | -2.02 |
| EPS Diluted Continuous Ops | 4.65 | -3.14 | -2.33 | -2.16 | -2.02 |
| EPS Diluted Before Non-Recurring Items | -2.32 | -3.14 | N/A | -2.16 | -2.02 |
| EBITDA(a) | $-94,540 | $-112,121 | $-81,363 | $-71,058 | $-64,059 |